A human, scientific, and entrepreneurial adventure
Hemarina is a biopharmaceutical company specialized in the development of health products via its proprietary technology platform (M101) based on the properties of Lugworm (Arenicola marina) hemoglobin. A spin-off of the CNRS and Sorbonne University (Paris VI), Hemarina was created in 2007 in Northern Finistère.
Convinced that this natural biopolymer had potential as an innovative therapeutic option to address diseases for which there are significant unmet medical needs, Franck Zal created his company based on fifteen years of fundamental research.
A major innovation compared to all the other current Hemoglobin-Based Oxygen Carriers (HBOCs) Hemarina’s unique technology in the world is based on a naturally occurring extracellular hemoglobin of high molecular weight, that is functional over a wide temperature range (from 4°C to 37°C) and does not require any cofactor to release oxygen. To date, this is the only known hemoglobin with these properties.
One of the essential advantages of this technology is the absence of vasoconstrictor and hypertensive effects as observed with first and second generation HBOCs manufactured from animal (bovine or porcine) or human hemoglobin.
The prospects for therapeutic applications are therefore immense. Why? Quite simply because this molecule is a technological platform; it can be used wherever oxygen is involved and potentially at all levels of the living organism (cell, tissue, organ and organism). As a result, all ischemic diseases (resulting from low blood flow and oxygen deficiency) are potential pathways for development.
The heart, kidney and brain are the most sensitive organs to oxygen deficiency. Therefore, these organs are the targets of technology development at Hemarina. Ischemia can result in heart failure, myocardial infarction, and stroke.
Another objective of Hemarina’s technology is to help blood banks meet the growing need for red blood cells. Currently, legal requirements state that human blood cells can be stored for a maximum of 42 days between +2° and +6°C. We are developing a freeze-drying system that will extend the storage life of our red blood cell-equivalent product for 5 years at room temperature.
This freeze-dried therapeutic oxygen carrier will be the first of its kind, and of major importance in the health sector. It will allow rapid use without a regulated storage chamber (equipment for SAMU vehicles, for first aid care) and no thawing constraints, thus providing an optimal solution for the treatment of crises.
Our current efforts focus on the development of the following health products:
- HEMO2life®: This medical device is an additive to graft preservation solution, Class III Medical Device (NB 2797) and has already earned the support of the scientific and medical community.
- HEMHealing®: an oxygenating dressing
- HEMOXYCarrier®: a universal therapeutic oxygen carrier (similar to red blood cells).
- HEMDental-Care®: a treatment for periodontal diseases.
- HEMOXCell®: a cell growth activator
The novelty and potential of these solutions have been recognized through numerous international collaborations with academic, clinical and pharmaceutical partners in Europe and the United States.
The results of this research have been published in numerous peer-reviewed scientific journals and protected by patents, thus forming the foundations of Hemarina’s technology.
Patients are at the heart of all our actions. Our ultimate objective is to provide solutions that contribute to improving the quality of life of patients and their families.
Continuous innovation for diseases with unmet medical needs is a priority.The objective is to provide maximum benefit with minimal changes in medical practices, thereby limiting the cost to the health system.